Statins for the primary prevention of cardiovascular disease

Fiona Taylor(Adelphi Laboratory Center), Hawkins Gay(Northwestern University)

Cochrane Database of Systematic Reviews

January 29, 2013

10.1002/14651858.cd004816.pub5

Cited by 1,833

Related Papers

Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial

|The Lancet Oncology|2017|431

Statins for the primary prevention of cardiovascular disease

|Cochrane Database of Systematic Reviews|2011|305

Quality of life in patients with advanced renal cell carcinoma given nivolumab versus everolimus in CheckMate 025: a randomised, open-label, phase 3 trial

|The Lancet Oncology|2016|219

Quality of life (QoL) and overall survival (OS) in patients (pts) with advanced clear-cell renal cell carcinoma (aRCC) treated with nivolumab (NIVI) vs. everolimus (EVE) in the phase III CheckMate 025 study.

|Journal of Clinical Oncology|2016|4